-DOCSTART- -X- O
Middle -X- _ B-Patient
East -X- _ I-Patient
respiratory -X- _ I-Patient
syndrome -X- _ I-Patient
( -X- _ I-Patient
MERS -X- _ I-Patient
) -X- _ I-Patient
, -X- _ O
an -X- _ O
emerging -X- _ O
infectious -X- _ O
disease -X- _ O
caused -X- _ O
by -X- _ O
MERS -X- _ O
coronavirus -X- _ O
( -X- _ O
MERS-CoV -X- _ O
) -X- _ O
, -X- _ O
has -X- _ O
garnered -X- _ O
worldwide -X- _ O
attention -X- _ O
as -X- _ O
a -X- _ O
consequence -X- _ O
of -X- _ O
its -X- _ O
continuous -X- _ O
spread -X- _ O
and -X- _ O
pandemic -X- _ O
potential -X- _ O
, -X- _ O
making -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
effective -X- _ O
vaccines -X- _ O
a -X- _ O
high -X- _ O
priority. -X- _ O
We -X- _ O
previously -X- _ O
demonstrated -X- _ O
that -X- _ O
residues -X- _ O
377–588 -X- _ O
of -X- _ O
MERS-CoV -X- _ O
spike -X- _ O
( -X- _ O
S -X- _ O
) -X- _ O
protein -X- _ O
receptor-binding -X- _ O
domain -X- _ O
( -X- _ O
RBD -X- _ O
) -X- _ O
is -X- _ O
a -X- _ O
very -X- _ O
promising -X- _ O
MERS -X- _ B-Intervention
subunit -X- _ I-Intervention
vaccine -X- _ I-Intervention
candidate -X- _ O
, -X- _ O
capable -X- _ O
of -X- _ O
inducing -X- _ O
potent -X- _ O
neutralization -X- _ O
antibody -X- _ O
responses. -X- _ O
In -X- _ O
this -X- _ O
study -X- _ O
, -X- _ O
we -X- _ O
sought -X- _ O
to -X- _ O
identify -X- _ O
an -X- _ O
adjuvant -X- _ O
that -X- _ O
optimally -X- _ O
enhanced -X- _ O
the -X- _ O
immunogenicity -X- _ B-Intervention
of -X- _ I-Intervention
S377–588 -X- _ I-Intervention
protein -X- _ I-Intervention
fused -X- _ I-Intervention
with -X- _ I-Intervention
Fc -X- _ I-Intervention
of -X- _ I-Intervention
human -X- _ I-Intervention
IgG -X- _ I-Intervention
( -X- _ I-Intervention
S377–588-Fc -X- _ I-Intervention
) -X- _ I-Intervention
. -X- _ O
Specifically -X- _ O
, -X- _ O
we -X- _ O
compared -X- _ O
several -X- _ O
commercially -X- _ O
available -X- _ O
adjuvants -X- _ O
, -X- _ O
including -X- _ O
Freund -X- _ B-Intervention
's -X- _ I-Intervention
adjuvant -X- _ I-Intervention
, -X- _ O
aluminum -X- _ B-Intervention
, -X- _ O
Monophosphoryl -X- _ B-Intervention
lipid -X- _ I-Intervention
A -X- _ I-Intervention
, -X- _ O
Montanide -X- _ B-Intervention
ISA51 -X- _ I-Intervention
and -X- _ O
MF59 -X- _ B-Intervention
with -X- _ O
regard -X- _ O
to -X- _ O
their -X- _ O
capacity -X- _ O
to -X- _ O
enhance -X- _ O
the -X- _ O
immunogenicity -X- _ O
of -X- _ O
this -X- _ O
subunit -X- _ B-Intervention
vaccine. -X- _ I-Intervention
In -X- _ O
the -X- _ O
absence -X- _ O
of -X- _ O
adjuvant -X- _ O
, -X- _ O
S377–588-Fc -X- _ O
alone -X- _ O
induced -X- _ O
readily -X- _ O
detectable -X- _ O
neutralizing -X- _ O
antibody -X- _ O
and -X- _ O
T-cell -X- _ O
responses -X- _ O
in -X- _ O
immunized -X- _ O
mice. -X- _ O
However -X- _ O
, -X- _ O
incorporating -X- _ B-Outcome
an -X- _ I-Outcome
adjuvant -X- _ I-Outcome
improved -X- _ I-Outcome
its -X- _ I-Outcome
immunogenicity. -X- _ I-Outcome
Particularly -X- _ O
, -X- _ O
among -X- _ O
the -X- _ O
aforementioned -X- _ O
adjuvants -X- _ O
evaluated -X- _ O
, -X- _ O
MF59 -X- _ B-Outcome
is -X- _ I-Outcome
the -X- _ I-Outcome
most -X- _ I-Outcome
potent -X- _ I-Outcome
as -X- _ I-Outcome
judged -X- _ I-Outcome
by -X- _ I-Outcome
its -X- _ I-Outcome
superior -X- _ I-Outcome
ability -X- _ I-Outcome
to -X- _ I-Outcome

induce -X- _ B-Outcome
the -X- _ I-Outcome
highest -X- _ I-Outcome
titers -X- _ I-Outcome
of -X- _ I-Outcome
IgG -X- _ I-Outcome
, -X- _ I-Outcome
IgG1 -X- _ I-Outcome
and -X- _ I-Outcome
IgG2a -X- _ I-Outcome
subtypes -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
neutralizing -X- _ I-Outcome
antibodies. -X- _ I-Outcome
The -X- _ I-Outcome
addition -X- _ I-Outcome
of -X- _ I-Outcome
MF59 -X- _ I-Outcome
significantly -X- _ I-Outcome
augmented -X- _ I-Outcome
the -X- _ I-Outcome
immunogenicity -X- _ I-Outcome
of -X- _ I-Outcome
S377–588-Fc -X- _ I-Outcome
to -X- _ I-Outcome
induce -X- _ I-Outcome
strong -X- _ I-Outcome
IgG -X- _ I-Outcome
and -X- _ I-Outcome
neutralizing -X- _ I-Outcome
antibody -X- _ I-Outcome
responses -X- _ I-Outcome
as -X- _ I-Outcome
well -X- _ I-Outcome
as -X- _ I-Outcome
protection -X- _ I-Outcome
against -X- _ I-Outcome
MERS-CoV -X- _ I-Outcome
infection -X- _ I-Outcome
in -X- _ I-Outcome
mice -X- _ I-Outcome
, -X- _ I-Outcome
suggesting -X- _ I-Outcome
that -X- _ I-Outcome
MF59 -X- _ I-Outcome
is -X- _ I-Outcome
an -X- _ I-Outcome
optimal -X- _ I-Outcome
adjuvant -X- _ I-Outcome
for -X- _ I-Outcome
MERS-CoV -X- _ I-Outcome
RBD-based -X- _ I-Outcome
subunit -X- _ I-Outcome
vaccines -X- _ I-Outcome
. -X- _ O

